Hello everyone from snowy NY. My spouse received his first kidney transplant 11/2018 and I just told him about this news.
Apparently, there is a new IV infusion for people who are very immunocompromised to help improve their health from getting covid19, since the vaccinations were not working as hoped for most people in this category. Just sharing. Take care, stay well.
It's a monoclonal antibody called PEMGARDA. This is great news for those of us who are immunosuppresed and have not responded well (or at all, like me) to the Covid vaccines - we will finally have protection! The idea of giving us antibodies is similar to the previous Evusheld, but unlike Evusheld it neutralizes the current variants. PEMGARDA was just granted an EUA by the FDA. It is administered IV with redosing every 3 months. I've already contacted my nephrologist to get it!
Coincidentally, my spouse alerted me to this as well. I had never heard of this company (invivyd) until now nor of the new drug, also known as pemvibart. I will contact my nephrologist for more on this treatment and its availability, as well as whether or not he recommends it.
It is particularly ironic because I have been trying for months to get updates on AstraZeneca's Supernova trial on the updated version of Evusheld, sipavibart (which they have claimed is effective in vitro against all Omicron descendant variants to date). AstraZeneca is saying that the results of the study will be publicized in the first half of 2024 (way overdue, based on their earlier projections). Perhaps with the FDA approval of Pemgarda, AstraZeneca will accelerate its timeline, and we will hear good news from them, too.
If these drugs meet their expectations, it would be a real game changer for our community. I am looking forward...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.